Amphotericin B use in a community hospital, with special emphasis on side effects

Clinical Infectious Diseases

Volumn 26, Issue 2, 1998, Pages 334-340

  Pathak, Anand ^a   Pien, Francis D ^a,b   Carvalho, Lori ^a  

^a STRAUB CLINIC AND HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; DIPHENHYDRAMINE; HEPARIN; HYDROCORTISONE; PARACETAMOL; PETHIDINE;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL PRACTICE; COMMUNITY HOSPITAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL;

EID: 0031929248     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516321     Document Type: Article

References (19)

1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
2. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287-91.
3. Gross MH, Pickard WW, Perfect JR. Retrospective review of amphotericin B use in a tertiary-care medical center. Am J Hosp Pharm 1987;44:1353-7.
4. Sarosi GA. Amphotericin B: still the 'gold standard' forantifungal therapy. Postgrad Med 1990;88(1):151-66.
5. Seabury JH, Dascomb HE. Experience with amphotericin B. Ann NY Acad Sci 1960-61;89:202-20.
6. Tynes BS, Utz JP, Bennett JE, Alling DW. Reducing amphotericin B reactions: a double-blind study. Am Rev Respir Dis 1963;87:264-8.
7. Sanford WG, Rasch JR, Stonehill RB. A therapeutic dilemma: the treatment of disseminated coccidioidomycosis with amphotericin B. Ann Intern Med 1962;56:553-63.
8. Miller RP, Bates JH. Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 1969;71:1089-95.
9. Medoff G, Dismukes WE, Meade RH III, Moses JM. A new therapeutic approach to Candida infections: a preliminary report. Arch Intern Med 1972;130:241-5.
10. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990;88(suppl 5N):22N-7N.
11. Grasela TH Jr, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:341-8.
12. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole vs. amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
13. Lister J. Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996;56(suppl 57):18-23.
14. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-16.
15. Graybill JR. Lipid formulations for amphotericin B: does the emperor need new clothes? [Editorial]. Ann Intern Med 1996;124:921-3.
16. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
17. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
18. Nicholl T, Phillips P, Jewesson PJ. Amphotericin B use in a major acute care hospital. Clin Ther 1994;16:28-40.
19. Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis 1987;9:403-7.